Clinical Data Revolution rockets on strong pancreatic cancer data PharmaphorumRevolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.Clinical DataOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib. Clinical DataOncologyRead full story Post navigation Previous: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priorityNext: Novo Nordisk and OpenAI forge alliance to drive speedy drug development Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026